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The tumor microenvironment is profoundly immuno-
suppressive, but exactly how this is coordinated and
maintained remains poorly understood. We show that
multiple transplantable and autochthonous mouse
tumors actively elicit a population of highly suppressive
regulatory T cells (Tregs) expressing the lipid phospha-
tase PTEN. These PTEN+ Tregs co-expressed PD-1,
Foxp3, and high levels of Eos (Ikzf4). PTEN signaling
acted to stabilize tumor-associated Tregs, maintaining
their suppressor activity and preventing conversion into
pro-inflammatory effector cells (“ex-Tregs”) in the face
of inflammation. Mice with a targeted deletion of PTEN
in Tregs (PTEN-Treg-KO mice) were healthy and fertile
when young, but gradually developed lupus-like autoim-
munity as they aged. Tumors implanted in young,
healthy PTEN-Treg-KO mice were unable to create the
normal immunosuppressive tumor microenvironment;
instead, tumors were constitutively immunogenic,
chronically inflamed, and could barely grow. In wild-
type mice with large, pre-established tumors, pharmaco-
logic inhibition of PTEN during the period following
chemotherapy or adoptive immunotherapy caused a
profound reconfiguration of the tumor microenviron-
ment. The normally suppressive intratumoral Tregs
became destabilized, and rapidly reprogrammed into
pro-inflammatory “ex-Tregs” expressing IL-2, IL-17 and
CD40L. The dominant APCs in the tumor changed
from tolerogenic DCs expressing high levels of PD-L1,
and were replaced by inflammatory myeloid DCs expres-
sing high levels of CD86, MHC class II, IL-6 and IL-12.
CD8+ effector T cells in the tumor, which had pre-
viously been unresponsive and PD-1+ (exhausted),
became activated and expressed IFNg and GzmB, and
mediated tumor regression. Pharmacologic inhibition of
PTEN was highly synergistic with conventional che-
motherapy, allowing a single modest, normally ineffec-
tive dose of chemotherapy to trigger rapid tumor
involution. This synergy was strictly immune-mediated,
and was lost in the absence of host CD8+ T cells. In
mice without tumors, identical PTEN+ Tregs were phy-
siologically elicited by exposure to apoptotic cells; and
PTEN-Treg-KO mice rapidly developed lupus-like auto-
immunity when repeatedly challenged with apoptotic
cells. The induction of PTEN+ Tregs by apoptotic cells
was driven by indoleamine 2,3-dioxygenase (IDO) in the
host, and was blocked by pharmacologic inhibition of
IDO. Taken together, these data identify the PTEN
pathway in Tregs as a potent immunosuppressive
mechanism in tumors. PTEN+ Tregs controlled the
downstream activation of inflammatory DCs and effec-
tor CD8+ T cells, and were part of the fundamental
mechanism of tolerance to apoptotic cells. The PTEN
pathway thus represents a potent, centrally-positioned
immunosuppressive mechanism in tumors, which is
amenable to pharmacologic inhibition and shows
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synergy with both adoptive immunotherapy and conven-
tional chemotherapy.
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